STADA to Launch its Movymia (biosimilar, teriparatide) to Treat Osteoporosis in 24 Countries

 STADA to Launch its Movymia (biosimilar, teriparatide) to Treat Osteoporosis in 24 Countries

STADA to Acquire GSK’s OTC Portfolio for the Expansion of its Consumer Health Business in Europe

Shots:

  • In early H2’19, STADA is launching its biosimilar teriparatide, Movymia as a cost-effective with the patent expiration of the reference product Forsteo leading to expansion of STADA’s biosimilar portfolio in the EU
  • Forsteo is a form of parathyroid hormone used to make the bones stronger, and to reduce the risk of fractures by stimulating bone formation and has produced sales of EUR 250M in a year in the EU
  • Movymia is a re-fillable multidose injection device called Movymia Pen and the treatment of osteoporosis is only active ingredient approved for osteoanabolic therapy

Click here to read full press release/ article | Ref: STADA | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post